Intrust Bank NA Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intrust Bank NA lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,673 shares of the biopharmaceutical company’s stock after purchasing an additional 53 shares during the period. Intrust Bank NA’s holdings in Regeneron Pharmaceuticals were worth $1,469,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Eudaimonia Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares during the last quarter. Drive Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 12 shares during the last quarter. MCF Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Sutton Wealth Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the last quarter. Finally, Clearview Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 13 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. UBS Group boosted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,353,323.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Insiders have sold a total of 10,195 shares of company stock worth $9,759,898 over the last three months. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $0.30 during trading hours on Tuesday, reaching $892.18. 49,701 shares of the company’s stock traded hands, compared to its average volume of 483,985. The firm has a market capitalization of $97.93 billion, a price-to-earnings ratio of 25.68, a P/E/G ratio of 2.54 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The business’s fifty day simple moving average is $946.89 and its two-hundred day simple moving average is $894.83. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $10.96 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.